Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.

Abstract

We aimed to study the risks of graft-versus-host disease (GVHD), non-relapse mortality (NRM) and survival outcomes of allogeneic stem cell transplantation (alloSCT) in patients with chronic lymphocytic leukemia (n = 17), Richter's syndrome (n = 14), or lymphoma (n = 18) after small molecule inhibitors (SMIs). Patients had a median of 4 prior therapies, including ibrutinib (n = 46; 94%), venetoclax (n = 19; 39%), and idelalisib (n = 6; 12%). Twenty-one (43%) had >1 SMI. P53 mutation was detected in 58% of patients. The 3-year overall and progression-free survival rates were 68% and 59%, respectively. The rates of grade II-IV and III-IV acute GVHD were 33% and 7%. The 1-year rates of chronic GVHD, NRM and relapse were 19%, 10% and 21%, respectively. Results were comparable to a historical control of patients who received alloSCT without a prior exposure to SMI. We conclude that a prior use of SMI does not impair the outcomes after alloSCT.

• Authors: Akash Mukherjee, Denái R Milton, Elias J Jabbour, Alison M Gulbis, Tapan Kadia, Nitin Jain, Celina Ledesma, Jan Burger, Alessandra Ferrajoli, William Wierda, L Jeffrey Medeiros, Hagop Kantarjian, Richard Champlin, Issa F Khouri
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 4 Pg. 885-893 (04 2022) ISSN: 1029-2403 [Electronic] United States
• PMID: 35225133 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Topics

• Graft vs Host Disease (diagnosis, etiology)
• Hematopoietic Stem Cell Transplantation (methods)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis, drug therapy)
• Lymphoma, Large B-Cell, Diffuse (etiology)
• Recurrence
• Stem Cell Transplantation (adverse effects)
• Transplantation Conditioning (methods)
• Treatment Outcome